Abstract 615: NXP900, a novel YES1/SRC kinase inhibitor in phase 1, demonstrates potent inhibition of proliferation in cell lines resistant to ALK and EGFR inhibitors

Neil O. Carragher; Enrique Poradosu; Ben King; Alison F. Munro; John C. Dawson; Asier Unciti-Broceta

doi:10.1158/1538-7445.AM2024-615

Abstract 615: NXP900, a novel YES1/SRC kinase inhibitor in phase 1, demonstrates potent inhibition of proliferation in cell lines resistant to ALK and EGFR inhibitors

Neil O. Carragher, Enrique Poradosu, Ben King, Alison F. Munro, John C. Dawson, Asier Unciti-Broceta

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	615-615
Journal	Cancer Research
Volume	84
Issue number	6_Supplement
DOIs	https://doi.org/10.1158/1538-7445.AM2024-615
Publication status	Published - 15 Mar 2024

Access to Document

10.1158/1538-7445.AM2024-615

https://aacrjournals.org/cancerres/article/84/6_Supplement/615/736499/Abstract-615-NXP900-a-novel-YES1-SRC-kinase

Cite this

@article{2330a145c99e4733b166f23c51e1a5e3,

title = "Abstract 615: NXP900, a novel YES1/SRC kinase inhibitor in phase 1, demonstrates potent inhibition of proliferation in cell lines resistant to ALK and EGFR inhibitors",

author = "Carragher, {Neil O.} and Enrique Poradosu and Ben King and Munro, {Alison F.} and Dawson, {John C.} and Asier Unciti-Broceta",

year = "2024",

month = mar,

day = "15",

doi = "10.1158/1538-7445.AM2024-615",

language = "English",

volume = "84",

pages = "615--615",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "6_Supplement",

}

TY - JOUR

T1 - Abstract 615: NXP900, a novel YES1/SRC kinase inhibitor in phase 1, demonstrates potent inhibition of proliferation in cell lines resistant to ALK and EGFR inhibitors

AU - Carragher, Neil O.

AU - Poradosu, Enrique

AU - King, Ben

AU - Munro, Alison F.

AU - Dawson, John C.

AU - Unciti-Broceta, Asier

PY - 2024/3/15

Y1 - 2024/3/15

U2 - 10.1158/1538-7445.AM2024-615

DO - 10.1158/1538-7445.AM2024-615

M3 - Article

SN - 0008-5472

VL - 84

SP - 615

EP - 615

JO - Cancer Research

JF - Cancer Research

IS - 6_Supplement

ER -